{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T21:00:56Z","timestamp":1771189256058,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s13555-020-00472-x","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T08:02:44Z","timestamp":1608278564000},"page":"173-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Two-Year US Pharmacovigilance Report on Brodalumab"],"prefix":"10.1007","volume":"11","author":[{"given":"Mark","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Rawnsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binu","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"472_CR1","unstructured":"Siliq [package insert]. Bridgewater, NJ: Bausch Health US, LLC. 2017.\nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label. Accessed 14 Dec 2020."},{"issue":"14","key":"472_CR2","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"472_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386.","journal-title":"Br J Dermatol"},{"issue":"13","key":"472_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181\u20139.","journal-title":"N Engl J Med"},{"key":"472_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19132","author":"K Papp","year":"2020","unstructured":"Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19132.","journal-title":"Br J Dermatol"},{"issue":"2","key":"472_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","volume":"82","author":"L Puig","year":"2020","unstructured":"Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator\u2013controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"472_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.36849\/JDD.2020.5138","volume":"19","author":"M Lebwohl","year":"2020","unstructured":"Lebwohl M, Leonardi C, Wu JJ, et al. One-year pharmacovigilance update of brodalumab [editorial]. J Drugs Dermatol. 2020;19(8):807\u20138.","journal-title":"J Drugs Dermatol"},{"key":"472_CR8","unstructured":"Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. The flu season [Internet]. Available from: https:\/\/www.cdc.gov\/flu\/about\/season\/flu-season.htm. 2018. Accessed 19 Oct 2020."},{"issue":"3","key":"472_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40257-020-00512-4","volume":"21","author":"A Gottlieb","year":"2020","unstructured":"Gottlieb A, Lebwohl M, Liu C, Israel RJ, Jacobson A. Malignancy rates in brodalumab clinical studies for psoriasis. Am J Clin Dermatol. 2020;21(3):421\u201330.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"472_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"472_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"K Reich","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014\u201323.","journal-title":"Br J Dermatol"},{"issue":"4","key":"472_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jphs.2018.12.006","volume":"139","author":"G Xu","year":"2019","unstructured":"Xu G, Xia M, Jiang C, et al. Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: a network meta-analysis. J Pharmacol Sci. 2019;139(4):289\u2013303.","journal-title":"J Pharmacol Sci"},{"key":"472_CR13","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","journal-title":"J Immunol Res"},{"issue":"5","key":"472_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40261-017-0500-9","volume":"37","author":"A Attia","year":"2017","unstructured":"Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig. 2017;37(5):439\u201351.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"472_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","volume":"19","author":"M Amin","year":"2018","unstructured":"Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19(1):1\u201313.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"472_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"472_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13555-020-00472-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00472-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T18:13:00Z","timestamp":1612375980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-020-00472-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00472-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}